Abstract
The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Current Respiratory Medicine Reviews
Title:When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis
Volume: 9 Issue: 3
Author(s): Mili E. Torok
Affiliation:
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Abstract: The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Export Options
About this article
Cite this article as:
Torok E. Mili, When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990016
DOI https://dx.doi.org/10.2174/1573398X113099990016 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Tuberculosis; Opportunities for Treatment Optimization (Executive Guest Editor: Jan-Willem C. Alffenaar)]
Current Pharmaceutical Design Structure, Biological Properties and Applications of Marine-derived Polysaccharides
Current Organic Chemistry Central Nervous System Manifestations in Systemic Lupus Erythematosus
Current Rheumatology Reviews Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Current Status and Prospective Application of Stem Cell-Based Therapies for Spinal Cord Injury
Current Stem Cell Research & Therapy An Update on Autoinflammatory Diseases
Current Medicinal Chemistry Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Current Status and Future of Antifungal Therapy for Systemic Mycoses
Recent Patents on Anti-Infective Drug Discovery New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Kawasakis Disease, Acrodynia, and Mercury
Current Medicinal Chemistry HPLC-DAD-Q-TOF/MS-Based Screening and Analysis of the Multiple Absorbed Bioactive Components in Rat Serum after Oral Administration of Xiexin Tang
Current Pharmaceutical Analysis Status Epilepticus: An Overview
Current Drug Metabolism Detection of Antibiotic Resistance Genes Among Multiple Drug Resistant Pseudomonas Aeruginosa Isolated from Clinical Sources in Selected Health Institutions in Kwara State
Infectious Disorders - Drug Targets Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Autoantibodies Associated with Psychiatric Disorders
Current Neurovascular Research